Clinical Trial Update: RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 clinical trial evaluating safety and efficacy of CABA-201, a CD19-CAR T cell therapy, in adults with systemic sclerosis (scleroderma), curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• CABA-201

Snippet

Sponsor: Cabaletta Bio | Conditions: Systemic Sclerosis, Scleroderma | Phase 1, Phase 2 | Status: RECRUITING